Custom service

Recombinant Antibody Production

Sequence in, protein out — any format, any scale.

Timeline: 3–5 weeks — from sequence to proteinYield: 10–200 mg/L — transient HEK293Formats: IgG, Fab, scFv — bispecific, fusion proteins

Once a sequence exists, the antibody stops being a biological sample and becomes a manufacturing specification. Recombinant production removes the hybridoma from the supply chain: no drift, no mycoplasma risk, no lot-to-lot variation from culture conditions, and the ability to change isotype, add a tag or convert to a fragment by editing a plasmid rather than repeating an immunisation.

Transient expression in HEK293 is the standard route for research quantities. Heavy and light chain plasmids are co-transfected at an optimised ratio, culture runs for 6–10 days with feeding, and the harvest is purified by protein A. Titres of 10–200 mg/L are typical, and the entire cycle from synthesised gene to purified protein takes three to five weeks. CHO is used where glycosylation must match a manufacturing profile or where a stable line is the eventual goal.

The main technical risks are chain imbalance and aggregation. Excess light chain is common and is removed during purification, but it reduces yield; an unbalanced ratio of plasmids is corrected at the transfection step. Aggregation is sequence-dependent and is identified in the first small-scale expression, before a large batch is committed.

Service Highlights

Where it fits

Recombinant production is the default whenever a sequence is available and the antibody must be reproducible: assay standards, reference reagents, in vivo studies, and any project heading toward a regulated submission. It is also the only practical way to produce fragments consistently at scale.

It is not the cheapest route for a one-off reagent from an existing hybridoma, and it cannot rescue a sequence that aggregates or expresses poorly without protein engineering. Where the parent antibody is a hybridoma with no sequence, sequencing comes first.

Documentation and QC

Each batch is released with reducing and non-reducing SDS-PAGE, SEC-HPLC reporting monomer and aggregate content, A280 concentration, endotoxin by LAL, and antigen-binding ELISA compared with a reference. Mass is confirmed by LC-MS for constructs where the expected mass is defined.

Frequently asked questions

What if the antibody does not express?

We test at small scale first. Where titre is low, the signal peptide, codon usage and heavy-to-light ratio are varied; where aggregation is the cause, the sequence is examined for liabilities and a stabilising mutation may be proposed.

Can you make a bispecific?

Yes — knob-into-hole, tandem scFv-Fc or CrossMab formats are available, with chain pairing confirmed by mass spectrometry and by analytical SEC.

Is the glycosylation the same as from a hybridoma?

Similar but not identical. HEK293 and CHO both produce complex-type glycans, but the profile differs from a mouse hybridoma. For assays where Fc glycosylation affects binding, this should be characterised rather than assumed.

Send the sequence in any format. We will check it for expression liabilities and tell you the expected yield before transfection, so a difficult construct is identified early.

Service Highlights

  • Any format from one plasmid set. IgG1–IgG4, Fab, scFv, VHH-Fc, bispecific and fusion constructs built by standard cloning.
  • Codon-optimised synthesis. Genes synthesised and sequence-verified before transfection, with signal peptide selected for the host.
  • Chain ratio optimisation. Heavy and light chain plasmids titrated in a small-scale test to maximise assembled IgG and minimise free light chain.
  • HEK293 and CHO. HEK293 for speed, CHO for glycosylation profiles closer to a manufacturing process.
  • Scale flexibility. 10 mg to 1 g from the same construct, without changing the molecule.
  • Sequence archived. Plasmids and sequence files supplied, so the antibody can be re-made anywhere.

How the work runs

  1. Sequence and format review

    Variable regions are checked for liabilities — unpaired cysteines, N-glycosylation sequons, aggregation-prone patches — and the format and tag are agreed.

  2. Gene synthesis and cloning

    Codon-optimised genes synthesised and cloned into expression vectors, with full sequencing of the final constructs.

  3. Small-scale expression test

    Transfection in 6-well or 50 mL format to measure titre and assembly, and to identify aggregation before scaling.

  4. Preparative transfection

    Polyethylenimine transfection at 1–5 L, fed-batch culture for 6–10 days, harvest at peak viability.

  5. Purification

    Protein A capture, ion exchange or SEC polishing as required, and buffer exchange into the final formulation.

  6. QC

    SDS-PAGE reducing and non-reducing, SEC-HPLC, A280, endotoxin and binding ELISA against the antigen.

Specifications & timeline

Timeline
3–5 weeks — from sequence to protein
Yield
10–200 mg/L — transient HEK293
Formats
IgG, Fab, scFv — bispecific, fusion proteins
Expression host
HEK293 (transient), CHO (transient or stable)
Scale
10 mg to 1 g; larger through stable pools
Titre
10–200 mg/L transient, higher in stable pools
Formats
IgG1–4, Fab, scFv, VHH-Fc, bispecific, Fc fusion, enzyme fusion
Timeline
3–5 weeks from sequence to purified protein
Deliverables
Purified protein, expression plasmids, sequence files, SDS-PAGE, SEC-HPLC, binding data

Related Products

Next step

Tell us the target, we will tell you what is feasible

Send the sequence, assay format and sensitivity you need. You will get a technical assessment — recommended platform, timeline and the risks worth knowing before you commit budget.